Skip to main content

Table 1 Baseline characteristics of patients newly diagnosed with ATTR-CM

From: Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis

Patients newly diagnosed with ATTR-CM
(n = 175)
 
Age (years), mean (SD) 69.3(13.5)
 < 65, n (%) 48 (27.4)
 ≥ 65 127 (72.6)
Sex, n (%)
 Male 110 (62.9)
 Female 65 (37.1)
Year of diagnosis, n (%)  
 2013 14 (8.0)
 2014 29 (16.6)
 2015 21 (12.0)
 2016 28 (16.0)
 2017 37 (21.1)
 2018 46 (26.3)
Type of hospital undergoing diagnosis, n (%)  
 Tertiary hospital 144 (82.3)
 General hospital 31 (17.7)
CCI, mean (SD) 2.71 (2.01)
 < 3 87 (49.7)
 ≥ 3 88 (50.3)
History of diseases, n (%)  
 Cardiac manifestation  
  Hypertension 90 (51.3)
  Atrial fibrillation 36 (20.6)
  Other cardiovascular diseases 95 (54.3)
 Non-cardiac manifestation  
  Musculoskeletal disease 119 (68.0)
  Depression, anxiety, insomnia 77 (44.0)
  Peripheral neuropathy 59 (33.7)
  Diabetes mellitus 57 (32.6)
  Malignancy 17 (9.7)
  Dementia 9 (5.1)
  1. ATTR-CM Transthyretin amyloid cardiomyopathy, CCI Charlson comorbidity index, SD Standard deviation